Louis Navellier’s Top 10 Stock Picks Heading into 2025

7. Novo Nordisk A/S (NYSE:NVO)

Navellier & Associates’ Stake Value: $14.1 million

Number of Hedge Funds Holders: 61

Novo Nordisk A/S (NYSE:NVO), headquartered in Bagsværd, near Copenhagen, Denmark, is a leading global healthcare company specializing in treatments for obesity, diabetes, and rare diseases. Operating in over 168 countries with a workforce of 48,000 employees, Novo Nordisk is renowned for its products, including Ozempic, Rybelsus, and Wegovy.

On November 22, BMO Capital reaffirmed its Outperform rating on Novo Nordisk A/S (NYSE:NVO) and maintained a $156 price target. The firm highlighted the potential positive impact on Novo Nordisk’s stock following developments involving its parent company, Novo Holdings. Reports suggest that Novo Holdings is likely to secure European Union antitrust approval for its proposed $16.5 billion acquisition of Catalent, which could strengthen Novo Nordisk’s strategic position.

In Q3 2024, Novo Nordisk A/S (NYSE:NVO) reported impressive growth, with sales rising 24% and operating profit increasing 22%. The company’s GLP-1 treatments for diabetes have continued to expand their reach, now serving over 43 million patients worldwide, further solidifying its leadership in the healthcare sector.